HK1036583A1 - use of d-serine or d-alanine for treating schizophrenia - Google Patents

use of d-serine or d-alanine for treating schizophrenia

Info

Publication number
HK1036583A1
HK1036583A1 HK01105482A HK01105482A HK1036583A1 HK 1036583 A1 HK1036583 A1 HK 1036583A1 HK 01105482 A HK01105482 A HK 01105482A HK 01105482 A HK01105482 A HK 01105482A HK 1036583 A1 HK1036583 A1 HK 1036583A1
Authority
HK
Hong Kong
Prior art keywords
alanine
cycloserine
serine
alkylated
precursor
Prior art date
Application number
HK01105482A
Other languages
English (en)
Inventor
Tsai Gouchuan
Coyle Joseph
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HK1036583A1 publication Critical patent/HK1036583A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK01105482A 1998-04-14 2001-08-07 use of d-serine or d-alanine for treating schizophrenia HK1036583A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8164598P 1998-04-14 1998-04-14
PCT/US1999/008056 WO1999052519A2 (en) 1998-04-14 1999-04-14 Methods for treating neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
HK1036583A1 true HK1036583A1 (en) 2002-01-11

Family

ID=22165468

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105482A HK1036583A1 (en) 1998-04-14 2001-08-07 use of d-serine or d-alanine for treating schizophrenia

Country Status (17)

Country Link
US (5) US6228875B1 (de)
EP (3) EP1844769A3 (de)
JP (1) JP2002511409A (de)
AT (1) ATE369848T1 (de)
AU (1) AU765603C (de)
CA (2) CA2601132C (de)
CY (1) CY1106898T1 (de)
DE (2) DE69936848T2 (de)
DK (1) DK1073432T3 (de)
ES (1) ES2164040T3 (de)
HK (1) HK1036583A1 (de)
HU (1) HUP0101627A3 (de)
IL (1) IL139008A0 (de)
NZ (1) NZ508160A (de)
PT (1) PT1073432E (de)
RU (1) RU2219924C2 (de)
WO (1) WO1999052519A2 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
KR20010072878A (ko) * 1998-10-16 2001-07-31 디르크 반테 인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE19918105C1 (de) * 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
ES2281439T3 (es) * 2000-08-25 2007-10-01 Research Corporation Technologies, Inc Uso de anticonvulsionantes a base de aminoacidos para tratar el dolor.
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6828351B2 (en) * 2000-11-01 2004-12-07 Sention, Inc. Methods and compositions for regulating memory consolidation
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7846913B2 (en) 2003-12-29 2010-12-07 Mcdevitt Jason Patrick Compositions and methods to treat recurrent medical conditions
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1935414A3 (de) * 2001-05-02 2010-08-18 Blanchette Rockefeller Neurosciences Institute Kohlenstoffanhydrase-Aktivatoren zur Erhöhung der Auffassungsgabe und der Merkfähigkeit
US20040235889A1 (en) * 2001-05-02 2004-11-25 Miao-Kun Sun Carbonic anhydrase activator for enhancing learning and memory
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
CA2471715A1 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JPWO2003068215A1 (ja) * 2002-02-14 2005-06-02 味の素株式会社 ミトコンドリア病用薬剤
CA2478808A1 (en) * 2002-03-15 2003-09-25 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1512013A2 (de) * 2002-06-10 2005-03-09 EVOTEC Neurosciences GmbH Diagnostische und therapeutische verwendung des steroidogenen akut regulatorischen proteins (star) für neurodegenerative erkrankungen
KR100446503B1 (ko) * 2002-06-19 2004-09-04 삼성전자주식회사 복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
WO2004005935A1 (ja) * 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
EP1551393A4 (de) 2002-07-30 2010-06-16 Peter Migaly Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen
FR2843590B1 (fr) 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
JP4745661B2 (ja) * 2002-08-22 2011-08-10 大日本住友製薬株式会社 統合失調症治療剤
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
JP2006515999A (ja) * 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
BR0317771A (pt) 2002-12-27 2005-11-22 Otsuka Pharma Co Ltd Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
US20070249537A1 (en) * 2003-01-23 2007-10-25 Supernus Pharmaceuticals, Inc. Absorption enhancing agents
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
MXPA05012391A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
EP1625333A1 (de) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Unabhängige heizeinheit und diese benutzende medikamentenabgabevorrichtung
WO2004112700A2 (en) * 2003-06-06 2004-12-29 The General Hospital Corporation Methods and compositions for modulating amyloid precursor protein translation
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005053703A1 (en) * 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
WO2005062894A2 (en) * 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
US20120225916A1 (en) * 2003-12-29 2012-09-06 Mcdevitt Jason P Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
EP1735057B1 (de) * 2004-03-22 2015-02-25 Apkarian Technologies LLC Methoden und formulierungen zur behandlung von chronischem neuropathischen schmerz
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
WO2006060186A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives for the treatment of dementia and related disorders
CA2590287A1 (en) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
EP1831201B1 (de) * 2004-12-21 2010-08-04 Merck Sharp & Dohme Ltd. Piperidin- und azetidinderivate als glyt1-inhibitoren
JP5340729B2 (ja) 2005-06-13 2013-11-13 メルク シャープ エンド ドーム リミテッド 治療剤
CA2615147A1 (en) * 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
DK1940467T3 (da) * 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
WO2007041025A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Radiolabeled glycine transporter inhibitors
AR060088A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
TW200820963A (en) * 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2664366C (en) * 2006-11-09 2018-09-04 Centre For Addiction And Mental Health Slc1a1 antipsychotic drug response markers
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
EP2111858A1 (de) * 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
GB0817379D0 (en) * 2008-09-23 2008-10-29 Merck Sharp & Dohme New use
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20120041066A1 (en) * 2010-08-16 2012-02-16 Lombard Jay L Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
EP2478899B1 (de) * 2009-09-14 2018-05-09 Shiseido Company, Ltd. Zusammensetzung zur linderung durch ultraviolettstrahlung herbeigeführter schäden
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8624052B2 (en) * 2010-11-12 2014-01-07 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
DK2782566T3 (da) 2011-11-21 2021-02-08 The Inst For Ethnomedicine L-serin til anvendelse ved behandling af neurodegenerative lidelser
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
KR101499299B1 (ko) * 2012-08-03 2015-03-09 연세대학교 산학협력단 Ｓｈａｎｋ2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
US20150209306A1 (en) * 2012-08-07 2015-07-30 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AT514349B1 (de) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylierte Aminosäuren (AAAAs)
US20160206583A1 (en) * 2013-08-27 2016-07-21 The Johns Hopkins University Amino acid treatment of seizures
EP2878335B1 (de) 2013-11-10 2018-01-03 Brainsgate Ltd. Implantat und implantationssystem für nervenstimulator
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2016132136A1 (en) 2015-02-18 2016-08-25 Aston University Diagnostic assay and treatment for preeclampsia
AU2016258624B2 (en) 2015-05-04 2021-07-29 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
JP2018526345A (ja) * 2015-08-04 2018-09-13 コンフルーエンス ファーマシューティカルズ，エルエルシー アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
CN105476976B (zh) * 2015-12-22 2018-09-25 广州瑞尔医药科技有限公司 药物组合物及其制备方法和应用
IL263153B2 (en) * 2016-05-25 2023-09-01 National Health Res Inst Method and composition to lower the psychotic and addictive disorder of ketamine
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
AU2018274767A1 (en) * 2017-05-25 2020-01-30 Glytech Llc. Combined therapy for NMDAR antagonist-responsive neuropsychiatric disorders
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
KR20200103662A (ko) * 2017-11-22 2020-09-02 콘서트 파마슈티컬즈, 인크. D-세린의 중수소화 유사체 및 그의 용도
KR101952443B1 (ko) * 2018-08-23 2019-02-26 주식회사 아스트로젠 신규한 마그네슘­세리네이트 화합물 및 이의 용도
WO2022098106A1 (ko) * 2020-11-04 2022-05-12 주식회사 오에이티씨 클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물
WO2023171106A1 (ja) * 2022-03-08 2023-09-14 ソシウム株式会社 Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873722A (en) 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
JPS5520747A (en) * 1978-08-01 1980-02-14 Sumitomo Chem Co Ltd Antidepressant
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5468763A (en) 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
DE4117629A1 (de) 1991-05-29 1992-12-03 Max Planck Gesellschaft Phospatidylserine
DE69315920T2 (de) 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
GB9300051D0 (en) 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
EP0696586A1 (de) * 1993-04-27 1996-02-14 Yamanouchi Pharmaceutical Co. Ltd. Serin-derivate
JPH0826986A (ja) * 1994-07-21 1996-01-30 Yamanouchi Pharmaceut Co Ltd 抗フェンサイクリジン薬
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
IL127244A (en) * 1996-05-31 2005-11-20 Allelix Neuroscience Inc Substituted amines, methods of their preparation and pharmaceutical compositions containing them
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
EP1086094A1 (de) 1998-05-23 2001-03-28 Byk Gulden Lomberg Chemische Fabrik GmbH Quinolin-aminomethyl-pyridyl derivate mit anti-helicobacter aktivität
US6551993B1 (en) 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction

Also Published As

Publication number Publication date
EP1073432A2 (de) 2001-02-07
EP1844769A2 (de) 2007-10-17
US6667297B2 (en) 2003-12-23
HUP0101627A2 (hu) 2001-10-28
US7704978B2 (en) 2010-04-27
EP2338482A3 (de) 2011-12-21
US20050250851A1 (en) 2005-11-10
PT1073432E (pt) 2007-10-22
CA2328197C (en) 2007-11-20
RU2219924C2 (ru) 2003-12-27
WO1999052519A3 (en) 1999-12-02
CY1106898T1 (el) 2012-09-26
IL139008A0 (en) 2001-11-25
EP1844769A3 (de) 2010-02-10
EP2338482A2 (de) 2011-06-29
DK1073432T3 (da) 2007-12-17
ES2164040T3 (es) 2008-02-01
CA2328197A1 (en) 1999-10-21
DE69936848T2 (de) 2008-05-15
AU3557199A (en) 1999-11-01
NZ508160A (en) 2004-01-30
US6420351B1 (en) 2002-07-16
ATE369848T1 (de) 2007-09-15
US20020193429A1 (en) 2002-12-19
JP2002511409A (ja) 2002-04-16
CA2601132C (en) 2011-11-08
US6228875B1 (en) 2001-05-08
US20020035145A1 (en) 2002-03-21
DE1073432T1 (de) 2002-02-07
US6974821B2 (en) 2005-12-13
AU765603B2 (en) 2003-09-25
US20040092530A1 (en) 2004-05-13
EP1073432B1 (de) 2007-08-15
WO1999052519A2 (en) 1999-10-21
CA2601132A1 (en) 1999-10-21
AU765603C (en) 2004-08-05
HUP0101627A3 (en) 2003-02-28
DE69936848D1 (de) 2007-09-27
ES2164040T1 (es) 2002-02-16

Similar Documents

Publication Publication Date Title
HK1036583A1 (en) use of d-serine or d-alanine for treating schizophrenia
HUT75248A (en) Pharmaceutical formulations containing thioctic acid, solide salts of thioctic acid with improved release and bioabsorption
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
EP1797878A3 (de) Benzothiazolderivate
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
BR0002073A (pt) Processo para a preparação de um composto quiral
CY1110448T1 (el) Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
IL131172A (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
EP1222922A4 (de) Methode zur stabilisierung von benzimidazol-verbindungen
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
HK1032542A1 (en) Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator
IL119417A (en) Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
AU2639299A (en) Remedies/preventives for parkinson's disease
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
BR9814127A (pt) Nova forma de dosagem oral para carvedilol
MY126117A (en) Pharmaceutical compositions
FR2732217B1 (fr) Forme d'administration solide a usage oral
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
GB9420747D0 (en) 1,5 benzodiazepine derivatives
BR9815004A (pt) Composições estabilizadas de amaciamento de tecidos.